Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Early prevention of myeloma: dara for high-risk MGUS and low-risk SMM

Irene Ghobrial • 6 Dec 2019
ASH 2019
Multiple Myeloma Rare Diseases Smoldering Myeloma Antibodies Daratumumab

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the first report of the efficacy and safety of the single-arm, phase II trial of daratumumab monotherapy in patients with low-risk smoldering multiple myeloma. Early therapeutic intervention in this precursor patient population appears promising and required long-term follow-up. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Irene Ghobrial

0:52
Using spatial proteomics to analyze the bone marrow microenvironment in SMM treated with nivolumab
Irene Ghobrial • 7 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
Early interception in SMM & novel agents being explored
Irene Ghobrial et al. • 25 Mar 2024
1:19
Single-cell sequencing of circulating tumor cells to predict progression from MGUS/SMM
Irene Ghobrial • 11 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals